Mesothelioma Clinical Trials

Researchers are assessing the safety of the drug VT3989 in people with mesothelioma. The people in this study have mesothelioma with a mutation (change or variant) in the NF2 gene.

Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:

Peritoneal mesothelioma is a cancer of the inner lining of the abdomen (belly). The people in this study will be having surgery to take out as much of the cancer as possible. They will also receive heated chemotherapy given directly into the abdomen to kill any remaining cancer cells.

Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).

If you join this study, you will be randomly assigned to get one of these treatments:

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.